Dr. Robin A. Robinson
Chief Scientific Officer

 

Dr. Robin A. Robinson is a respected authority on the development of breakthrough biomedical technologies, and a seasoned expert in consummating collaborations with leading US government agencies, Fortune 500 companies, academic research groups, and foreign governments, for which he was cited in 2018 as one of the top 100 innovators in medicine by The Medicine Maker.

Notably, Dr. Robinson was appointed as the first Director of the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services, with an annual budget of $1.35 billion and a staff of 250 scientists and medical experts. He brought BARDA into prominence as one of the top 10 fully integrated R&D organizations worldwide supporting advanced development and acquisition of more than 240 drugs, vaccines, diagnostics, and medical devices for man-made biodefense threats, pandemic influenza, and emerging infectious diseases including Ebola and Zika viruses. 32 of these medical countermeasure products that BARDA supported were approved and licensed by the FDA during his 12-year tenure.

He concurrently served as Deputy Assistant Secretary, Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services (Washington, D.C.), under appointment by HHS Secretary Michael Leavitt. Prior to his public service work at BARDA, he served as Director vaccines at Novavax, Inc. resulting in the discovery and development of more than 12 vaccine candidates. Before entering the pharmaceutical industry, he was an assistant professor in the Department of Microbiology and Immunology at the University of Texas Southwestern Medical School conducting research on the molecular pathogenesis of herpesviruses and HIV-1.

During his tenure at BARDA, Dr. Robinson initiated over $535 million in contracts for skin regeneration, burns, stem cell therapies, and related technologies to treat thermal and radiation burn wounds.

Dr. Robin Robinson is a consummate deal maker, having successfully established over 60 partnerships with federal agencies, including the United States Food & Drug Administration (FDA), Centers for Disease Control and Prevention, National Institutes of Health, US Army Medical Research Institute of Infectious Diseases, The Defense Advanced Research Projects Agency (DARPA), The Joint Program Executive Office for Chemical and Biological Defense, and the Defense Threat Reduction Agency.

His more than 80 non-governmental and commercial partnerships included the Gates Foundation, Wellcome-Trust, Sanofi, GlaxoSmithKline plc, Novartis, Merck, Roche/Genentech, Amgen, Johnson & Johnson (Crucell), SIGA, Regeneron and Emergent and many others.

Dr. Robinson has developed collaborations with universities and foreign governments, including the Johns Hopkins University, North Carolina State, and the United Kingdom, Canada, Australia, France, Germany, and others.

At RenovaCare, Dr. Robinson is responsible for setting the Company’s scientific strategy and leading our scientific and engineering teams in research & development activities. Dr. Robinson is a key participant in new product innovation and development and is charged with advancing the Company’s technology along its FDA submission pathway.

Dr. Robinson oversees and directs RenovaCare strategy, execution and engagement with government agencies, contract research organizations, academic institutions and select opinion leaders.

Dr. Robinson Chairs the RenovaCare Scientific Advisory Board.